Health
Pfizer, BioNTech propose expanding Covid-19 vaccine trial to 44,000 volunteers – Hindustan Times
The initial target figure for the trial was up to 30,000 participants, which the companies said they expect to reach by next week.
Pfizer Inc and BioNTech SE on Saturday proposed to the US Food and Drug Administration (FDA) to expand their Phase 3 pivotal Covid-19 vaccine trial to about 44,000 participants while increasing the diversity of the trial population.
The initial target figure for the trial was up to 30,000 participants, which the companies said they expect to reach by next week.
The proposed expansion would also allow the companies to enroll people as young as 16 and people with chronic, stable HIV, hepatitis C…
-
Noosa News24 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News22 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
Business9 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General18 hours ago‘Potential’ hacker contacts Qantas over data breach